Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure. Global Banking & Finance Review® operates a Digital-First Banking Awards Program and framework — an industry-first digital only recognition model built for the modern financial era, delivering continuous, transparent, and data-driven evaluation of institutional performance.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > EU approves higher dose of Novo Nordisk's Wegovy
    Finance

    EU approves higher dose of Novo Nordisk's Wegovy

    Published by Global Banking & Finance Review®

    Posted on February 17, 2026

    1 min read

    Last updated: February 17, 2026

    EU approves higher dose of Novo Nordisk's Wegovy - Finance news and analysis from Global Banking & Finance Review
    Tags:innovationhealthcaresustainabilityfinancial communityinsurance

    Quick Summary

    The European Commission approved a higher dose of Novo Nordisk's weight-loss drug Wegovy, potentially enhancing its effectiveness.

    Table of Contents

    • EU Approval of Wegovy's Higher Dosage
    • Details of the 7.2 mg Dosage
    • Trial Results and Efficacy
    • Future Approval for Single-Dose Pen

    EU Greenlights Higher Dosage of Novo Nordisk's Wegovy Obesity Drug

    EU Approval of Wegovy's Higher Dosage

    Feb 17 (Reuters) - Novo Nordisk said on Tuesday the European Commission has approved a higher dose of its popular obesity drug Wegovy, providing patients and doctors with an option that may support greater weight loss.

    Details of the 7.2 mg Dosage

    The decision follows a positive recommendation from the European Union's drug regulator in December for the drug's 7.2 milligram dose.

    Trial Results and Efficacy

    With the approval, doctors in the EU may now prescribe the 7.2 mg dosage as three 2.4 mg injections, to be taken in one sitting, once a week, the Danish drugmaker said.

    Future Approval for Single-Dose Pen

    In a 72-week late-stage trial involving 1,407 adults without diabetes, participants on the 7.2 mg dose lost an average of 20.7% of body weight, compared with 17.5% for the 2.4 mg dose.

    Novo has also applied for an EU approval of a 7.2 mg single-dose pen. If approved, this could be available this year, the company said.

    (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)

    Key Takeaways

    • •European Commission approves higher dose of Wegovy.
    • •Novo Nordisk's weight-loss drug gets a dosage boost.
    • •New approval could impact weight-loss treatment options.
    • •Danish drugmaker Novo Nordisk announces the approval.
    • •Potential market implications for Novo Nordisk.

    Frequently Asked Questions about EU approves higher dose of Novo Nordisk's Wegovy

    1What is Wegovy?

    Wegovy is a prescription medication developed by Novo Nordisk for weight management. It is used alongside a reduced-calorie diet and increased physical activity to help individuals lose weight and maintain weight loss.

    2What is the European Commission?

    The European Commission is the executive branch of the European Union responsible for proposing legislation, implementing decisions, and managing the day-to-day operations of the EU.

    3What is weight loss medication?

    Weight loss medication is a type of pharmaceutical drug designed to help individuals lose weight by suppressing appetite, increasing feelings of fullness, or reducing the absorption of fat.

    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Previous Finance PostElliott builds over 10% stake in Norwegian Cruise, seeks board change
    Next Finance PostEU says no short-term oil supply risk in Hungary, Slovakia
    More from Finance

    Explore more articles in the Finance category

    Image for Carrefour confident for 2026, Cora & Match acquisition weighs on 2025 operating profit
    Carrefour confident for 2026, Cora & Match acquisition weighs on 2025 operating profit
    Image for German gas supply secure, no market intervention needed, says ministry
    German gas supply secure, no market intervention needed, says ministry
    Image for Exclusive-Arbitration claim puts pressure on logistics firm Access World, accounts show
    Exclusive-Arbitration claim puts pressure on logistics firm Access World, accounts show
    Image for Sweden and others oppose calls to delay new EU carbon market
    Sweden and others oppose calls to delay new EU carbon market
    Image for Israel's ZIM workers ramp up strike in protest over Hapag-Lloyd takeover
    Israel's ZIM workers ramp up strike in protest over Hapag-Lloyd takeover
    Image for UK power firm SSE to invest up to $1.28 billion for Scottish subsea cable upgrade  
    UK power firm SSE to invest up to $1.28 billion for Scottish subsea cable upgrade  
    Image for Analysis-Europe squares up to Big Tech, risking ire of Washington
    Analysis-Europe squares up to Big Tech, risking ire of Washington
    Image for Raspberry Pi soars 40% as CEO buys stock, AI chatter builds
    Raspberry Pi soars 40% as CEO buys stock, AI chatter builds
    Image for Soccer-LaLiga wins court orders forcing VPNs to block 16 alleged pirate sites
    Soccer-LaLiga wins court orders forcing VPNs to block 16 alleged pirate sites
    Image for France's AI company Mistral buys cloud service startup Koyeb
    France's AI company Mistral buys cloud service startup Koyeb
    Image for Germany pursues stake purchase in tank maker KNDS to keep influence, sources say
    Germany pursues stake purchase in tank maker KNDS to keep influence, sources say
    Image for Elliott builds over 10% stake in Norwegian Cruise, seeks board change
    Elliott builds over 10% stake in Norwegian Cruise, seeks board change
    View All Finance Posts